Catalio Capital Management, LP Ascendis Pharma A/S Transaction History
Catalio Capital Management, LP
- $411 Billion
- Q1 2025
A detailed history of Catalio Capital Management, LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Catalio Capital Management, LP holds 195,523 shares of ASND stock, worth $30.9 Million. This represents 7.41% of its overall portfolio holdings.
Number of Shares
195,523
Previous 215,587
9.31%
Holding current value
$30.9 Million
Previous $29.7 Billion
2.68%
% of portfolio
7.41%
Previous 6.49%
Shares
2 transactions
Others Institutions Holding ASND
# of Institutions
270Shares Held
61.9MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.63 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$866 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$825 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$709 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$673 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.82B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...